Skip to Content

Early-Onset IBD: Genetic Testing and Clinical Applications

Expiration date: August 13, 2021


Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic for a discussion of this testing and its clinical application.

View the Archived Webinar

Length of Video: 36 minute


Image of Ann Moyer, M.D., Ph.D.Ann Moyer, M.D., Ph.D.
Assistant Professor of Laboratory Medicine and Pathology
Division of Clinical Biochemistry and Immunology
Mayo Clinic, Rochester, Minnesota

Image ofMichael Stephens, M.D.Michael Stephens, M.D.
Division Chair, Pediatrics Gastroenterology and Hepatology
Department of Pediatric Gastroenterology
Mayo Clinic, Rochester, Minnesota

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe clinical features of early-onset IBD.
  • List genes associated with early-onset IBD.
  • Discuss how testing modalities and variant classification may impact genetic test results.

Intended Audience

Clinicians who see IBD patients: gastroenterologists, hepatologists, primary care internal medicine, family medicine, nurse practitioners, physician assistants, laboratory directors, lab supervisors, and laboratory sendout managers.


The following types of credit are offered for this event:

To obtain credit:

  1. Watch the video.
  2. Complete the posttest and evaluation that launches immediately following the video.
  3. Generate and print your certificate(s).

Level of instruction for this program is intermediate.


Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of .5 P.A.C.E.® contact hour.

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

MCL Education

MCL Education

This post was developed by our Education and Technical Publications Team.